TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled Trial of the Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome
Brief Summary: Turners Syndrome is a genetic condition in females that is a result of abnormal chromosomes. Girls with Turner syndrome are very short as children and as adults. Although their growth hormone secretion is almost always normal, giving injections of growth hormone to Turner syndrome girls may increase their rate of growth. In addition, most girls with Turner syndrome do not have normal ovaries.

In normal girls the ovaries begin producing small amounts of the female sex hormone, estrogen at about 11 - 12 years of age. As girls grow older the level of estrogen increases. Estrogen is responsible for the changes in girls known as feminization. During feminization the hips grow wider, the breasts develop, there is an increase in the rate of growth, and eventually girls experience their first menstrual period.

This study was designed to evaluate the effect of low dose estrogen, growth hormone, and the combination of low dose estrogen and growth hormone on adult height in girls with Turner syndrome. Patients will be entered into the study from ages 5 to 12 and will be randomly placed into one of four groups.

1. Group one will receive low dose estrogen
2. Group two will receive growth hormone
3. Group three will receive both low dose estrogen and growth hormone
4. Group four will receive a placebo "sugar pill"

Once started, the treatment will continue until the patients approach their adult height, and growth slows to less than 1/2 inch over the preceding year. This usually occurs by the age of 15 or 16.

Patients will be seen at the outpatient clinic every 6 months during the study and will receive a routine check-up with blood and urine tests, and hand/wrist X-rays to determine bone age. On patient's yearly visits they will have the density of bone measured in their spine and forearm.


Options:
A: Arm Label: 4 mg estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol | Arm Label: 2 mg estradiol; Type: PLACEBO_COMPARATOR; Interventions: Drug: estradiol | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): 2 mg estradiol, 4 mg estradiol
B: Intervention Type: DRUG; Name: Growth Hormone (Humatrope); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ethinylestradiol / Norethisterone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol / Progesterone | Intervention Type: DRUG; Name: Ethinylestradiol / Norethisterone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Estradiol / Progesterone; Assigned to Arm(s): 2
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 B estradiol orally | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 B estradiol | Intervention Type: DRUG; Name: 17 B estradiol orally; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: 17 B estradiol; Assigned to Arm(s): Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Population Differences in the Insulin Sensitivity, Resting Energy Expenditure, and Body Composition of Overweight Children and Children of Overweight Parents
Brief Summary: This study focuses on the way weight is gained. Individuals who gain weight primarily in their midsection (visceral weight) are at an increased risk for developing diabetes and high blood pressure.

Research has shown that African Americans suffer more often from high blood pressure, diabetes (non-insulin dependent), and heart disease than Caucasian Americans. These conditions lead to significant numbers of deaths and diseases associated with and made worse by obesity.

African American women in particular suffer from obesity and the associated conditions of obesity more than any other race or gender. However, it is unknown if the conditions seen in African American women are a result of the obesity or differences in their insulin sensitivity, glucose disposal, or fat metabolism.

This study will compare body composition, total and resting energy expenditure, and glucose disposal of obese African American and Caucasian children and of non-obese children of obese African American and Caucasian parents, to characterize the timing and nature of factors that may contribute to the prevalence of obesity and its complications.

Patients participating in this study will be followed for 15 years and be evaluated every 5 years during the study.\<TAB\>


Options:
A: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide
B: Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): N/A
C: N/A
D: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions
Brief Summary: Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals with the onset of obesity during childhood or adolescence are at an increased risk of obesity-related, diseases, both during adolescence and later in adult life.

African American girls and women are at an increased risk for obesity, and have substantial rates of obesity-related diseases and causes of death. Further, many African American adult women fail to respond to many of the therapeutic approaches used to treat obesity. At present there are no medical therapies proven effective for the correction of severe obesity in children or adolescents.

One medication that may have a favorable risk-benefit ratio in pediatric populations is Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten in the diet. Xenical appears to be effective for reducing weight and obesity-associated diseases in obese adults.

Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17 year old severely obese African American and Caucasian children and adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Rosiglitazone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Program | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Lifestyle Program; Assigned to Arm(s): 3
B: Arm Label: Depression Prevention; Type: EXPERIMENTAL; Interventions: Other: The Blues Program | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Other: Hey Durham | Intervention Type: OTHER; Name: The Blues Program; Assigned to Arm(s): Depression Prevention | Intervention Type: OTHER; Name: Hey Durham; Assigned to Arm(s): Health Education
C: N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Orlistat; Type: EXPERIMENTAL; Interventions: Drug: Orlistat | Intervention Type: DRUG; Name: Orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy plus chemotherapy is more effective than radiation therapy alone in treating patients with advanced head and neck cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients with advanced head and neck cancer.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I
B: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
C: Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: low-LET cobalt-60 gamma ray therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: low-LET photon therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining radiation therapy and surgery with chemotherapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare radiation therapy alone before surgery with radiation therapy plus fluorouracil and leucovorin before surgery, with and without fluorouracil and leucovorin after surgery in patients with rectal cancer that can be surgically removed.


Options:
A: Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
C: Arm Label: S-1 and Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 & Oxaliplatin | Arm Label: Capecitabine and Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine & Oxaliplatin | Intervention Type: DRUG; Name: S-1 & Oxaliplatin; Assigned to Arm(s): S-1 and Oxaliplatin | Intervention Type: DRUG; Name: Capecitabine & Oxaliplatin; Assigned to Arm(s): Capecitabine and Oxaliplatin
D: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.


Options:
A: Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Radiation therapy; Type: EXPERIMENTAL; Interventions: Radiation: radiation therapy | Arm Label: Radiation plus PCV chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Radiation plus PCV chemotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiation plus PCV chemotherapy, Radiation therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Conformal radiotherapy | Arm Label: 2; Type: OTHER; Interventions: Radiation: Conventional radiotherapy | Intervention Type: RADIATION; Name: Stereotactic Conformal radiotherapy; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): 2
C: Arm Label: Radiation therapy (RT) alone; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: Intensive pre-treatment chemotherapy and radiation therapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy, Radiation therapy (RT) alone
D: Arm Label: radiotherapy; Type: OTHER; Interventions: Radiation: radiation therapy | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): radiotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.


Options:
A: Arm Label: Radiation therapy (RT) alone; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: Intensive pre-treatment chemotherapy and radiation therapy; Type: EXPERIMENTAL; Interventions: Drug: lomustine, Drug: procarbazine hydrochloride, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Intensive pre-treatment chemotherapy and radiation therapy, Radiation therapy (RT) alone
B: Arm Label: Arm 1 - Short Course Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy | Arm Label: Arm 2 - Standard Course Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 1 - Short Course Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Arm 2 - Standard Course Radiotherapy
C: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Radiotherapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: QUADRANTECTOMY PLUS AXILLARY DISSECTION VERSUS QUADRANTECTOMY ALONE IN MAMMOGRAPHIC STAGE T1N0 BREAST CANCER PATIENTS AGED OVER 65 YEARS
Brief Summary: RATIONALE: Surgery to remove axillary lymph nodes may be an effective treatment for women with breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of therapy with or without axillary lymph node dissection following quadrantectomy in treating older women with stage I breast cancer that is estrogen receptor positive.


Options:
A: Arm Label: Arm I: Conventional axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional surgery | Arm Label: Arm II: Sentinel node resection followed by node examination; Type: EXPERIMENTAL; Interventions: Procedure: Sentinel node resection followed by node examination | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I: Conventional axillary dissection | Intervention Type: PROCEDURE; Name: Sentinel node resection followed by node examination; Assigned to Arm(s): Arm II: Sentinel node resection followed by node examination
B: Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
C: Arm Label: axillary lymph node dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: axillary lymph node dissection, Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery | Arm Label: axillary radiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery, Radiation: radiation therapy | Intervention Type: PROCEDURE; Name: axillary lymph node dissection; Assigned to Arm(s): axillary lymph node dissection | Intervention Type: PROCEDURE; Name: lymphoscintigraphy; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): axillary radiotherapy
D: Arm Label: Axillary Dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary lymph node dissection | Arm Label: No Axillary Dissection; Type: EXPERIMENTAL; Interventions: Procedure: No axillary lymph node dissection | Intervention Type: PROCEDURE; Name: Axillary lymph node dissection; Assigned to Arm(s): Axillary Dissection | Intervention Type: PROCEDURE; Name: No axillary lymph node dissection; Assigned to Arm(s): No Axillary Dissection

Answer: B